USFDA OKs Advair Generic: Aurobindo Gains, Cipla Faces Setback

HEALTHCAREBIOTECH

Overview

The U.S. Food and Drug Administration has granted final approval for a generic version of the respiratory drug Advair Diskus. This development is seen as a win for Aurobindo Pharma, which is acquiring Lannett, the entity that received approval, and a blow to Cipla, which has been awaiting its own generic Advair approval. Increased competition from the latest nod is expected to negatively impact Cipla's market share and sales projections.

USFDA Approves Generic Advair Diskus

The U.S. Food and Drug Administration (USFDA) has granted final approval for a generic version of the Advair Diskus, a critical medication used to treat asthma and chronic obstructive pulmonary disease (COPD). This significant regulatory milestone was achieved by Respirent Pharmaceuticals and Lannett.

Aurobindo Pharma Poised for Growth

The approval is a clear positive for Aurobindo Pharma. The company announced in July 2025 its intention to acquire Lannett for $250 million. While the transaction is still pending, with analysts expecting completion within the next two months, the inclusion of this newly approved generic Advair product is anticipated to significantly benefit Aurobindo Pharma.

Cipla Faces Intensified Competition

Conversely, this development presents a considerable challenge for Cipla. The pharmaceutical firm had filed its own generic Advair version as early as 2020 and has been awaiting final approval. Street estimates projected peak sales of around $100 million for Cipla's generic Advair, with a potential launch anticipated in the second half of fiscal year 2027.

Market Dynamics Shift

The approval adds to existing competition, with Mylan, now operating as Viatris, having already secured approval for its generic Advair in 2019. Brokerage firm Nuvama highlighted that the increased competitive intensity stemming from this latest approval is detrimental to Cipla. The firm indicated it raises the risk to Cipla's market share and could impact its peak sales expectations for its Advair inhaler opportunity.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.